(Q51701640)

10 April 2018

title

KRAS testing and its importance in colorectal cancer. (English)

1 reference

10 April 2018

1 reference

Deepa T Patil

1

1 reference

10 April 2018

Cory R Fraser

series ordinal

2

1 reference

10 April 2018

Thomas P Plesec

series ordinal

3

1 reference

10 April 2018

publication date

1 May 2010

1 reference

10 April 2018

published in

Current Oncology Reports

1 reference

10 April 2018

volume

12

1 reference

10 April 2018

issue

3

1 reference

10 April 2018

page(s)

160-167

1 reference

10 April 2018

https://scigraph.springernature.com/pub.10.1007/s11912-010-0099-y

exact match

0 references

cites work

Sensitive sequencing method for KRAS mutation detection by Pyrosequencing

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-010-0099-Y

Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives

21 January 2018

1 reference

12 December 2020

PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer

1 reference

12 December 2020

Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study

1 reference

12 December 2020

Guilty as charged: B-RAF is a human oncogene

1 reference

12 December 2020

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

1 reference

12 December 2020

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection

1 reference

12 December 2020

Hyperactive Ras in developmental disorders and cancer

1 reference

12 December 2020

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

12 December 2020

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

12 December 2020

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

1 reference

12 December 2020

Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis

1 reference

12 December 2020

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

12 December 2020

Cancer statistics, 2009

1 reference

12 December 2020

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

12 December 2020

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

12 December 2020

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

12 December 2020

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

1 reference

12 December 2020

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

12 December 2020

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

12 December 2020

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

1 reference

12 December 2020

A genetic model for colorectal tumorigenesis

1 reference

12 December 2020

Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.

1 reference

12 December 2020

Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number

1 reference

12 December 2020

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

12 December 2020

Targeting RAS signalling pathways in cancer therapy

1 reference

12 December 2020

KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology

1 reference

12 December 2020

The epidermal growth factor receptor as a target for colorectal cancer therapy

1 reference

12 December 2020

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

12 December 2020

EGFR antagonists in cancer treatment

1 reference

12 December 2020

KRAS mutation testing in colorectal cancer

1 reference

12 December 2020

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

12 December 2020

Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study

1 reference

12 December 2020

Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers

1 reference

12 December 2020

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

12 December 2020

Targeting the epidermal growth factor receptor for cancer therapy

1 reference

12 December 2020

Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system

1 reference

12 December 2020

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

1 reference

12 December 2020

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

12 December 2020

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

12 December 2020

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

12 December 2020

KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer

1 reference

12 December 2020

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

12 December 2020

High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer

1 reference

12 December 2020

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

12 December 2020

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

12 December 2020

The Kras2 oncogene and mouse lung carcinogenesis

1 reference

12 December 2020

Recurrent KRAS codon 146 mutations in human colorectal cancer

1 reference

12 December 2020

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

1 reference

12 December 2020

10.1007/S11912-010-0099-Y

Identifiers

DOI

1 reference

10 April 2018

1 reference

10 April 2018